Simoa® Ultra-sensitive Biomarker Detection  

In Dried Blood and Plasma Spots for Alzheimer’s Disease 

App Note

Blood-based biomarkers have transformed Alzheimer’s disease (AD) diagnostics, offering minimally invasive and cost-effective solutions. However, traditional AD blood testing presents logistical challenges, including the need for venous blood draws, specialized lab infrastructure, and temperature-controlled transport. Read this app note to learn how Simoa® technology is paving the way for next-generation biomarker research. 

Fill out the form to download the App Note

By submitting the form you agree to Quanterix’s Terms and Conditions.  If you have subscribed to our email marketing you can unsubscribe at any time, and you can learn more about how we manage your personal details in our Privacy Policy.